Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology.

[1]  Chiun Hsu,et al.  Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives , 2021, Seminars in Liver Disease.

[2]  J. Llovet,et al.  Evidence-based management of HCC: Systematic review and meta-analysis of randomized controlled trials (2002-2020). , 2021, Gastroenterology.

[3]  V. Mazzaferro,et al.  Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma. , 2021, Gastroenterology.

[4]  Jakob Nikolas Kather,et al.  Artificial intelligence-based pathology for gastrointestinal and hepatobiliary cancers , 2020, Gut.

[5]  J. Furuse,et al.  Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma , 2020, Journal of hepatology.

[6]  Yumin Li,et al.  The advances in immunotherapy for hepatocellular carcinoma , 2020 .

[7]  Jakob Nikolas Kather,et al.  Development of AI-based pathology biomarkers in gastrointestinal and liver cancer , 2020, Nature Reviews Gastroenterology & Hepatology.

[8]  Ming Y. Lu,et al.  AI-based pathology predicts origins for cancers of unknown primary , 2020, Nature.

[9]  Alexander T. Pearson,et al.  Clinical-grade Detection of Microsatellite Instability in Colorectal Tumors by Deep Learning. , 2020, Gastroenterology.

[10]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[11]  P. Chow,et al.  IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. , 2020, Future oncology.

[12]  Ming Y. Lu,et al.  Data-efficient and weakly supervised computational pathology on whole-slide images , 2020, Nature Biomedical Engineering.

[13]  Oumeima Laifa,et al.  Predicting Survival After Hepatocellular Carcinoma Resection Using Deep Learning on Histological Slides , 2020, Hepatology.

[14]  J. Xia,et al.  CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma , 2020, Cancer Immunology, Immunotherapy.

[15]  M. Ziol,et al.  Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma , 2020, Hepatology.

[16]  M. Ziol,et al.  Molecular and histological correlations in liver cancer. , 2019, Journal of hepatology.

[17]  T. Chan,et al.  The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy , 2019, Nature Reviews Cancer.

[18]  M. Kudo,et al.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[19]  N. Razavian,et al.  Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning , 2018, Nature Medicine.

[20]  J. Llovet,et al.  Molecular therapies and precision medicine for hepatocellular carcinoma , 2018, Nature Reviews Clinical Oncology.

[21]  Gisela Schwab,et al.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.

[22]  A. Luciani,et al.  Macrotrabecular‐massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance , 2018, Hepatology.

[23]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[24]  S. Imbeaud,et al.  Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. , 2017, Journal of hepatology.

[25]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[26]  Steven J. M. Jones,et al.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.

[27]  Peter Bankhead,et al.  QuPath: Open source software for digital pathology image analysis , 2017, Scientific Reports.

[28]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[29]  A. Luciani,et al.  Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features , 2016, Hepatology.

[30]  T. Gajewski,et al.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.

[31]  Elena Deza,et al.  Encyclopedia of Distances , 2014 .

[32]  P. Legendre,et al.  Ward's Hierarchical Clustering Method: Clustering Criterion and Agglomerative Algorithm , 2011, ArXiv.

[33]  Rodney X. Sturdivant,et al.  Applied Logistic Regression: Hosmer/Applied Logistic Regression , 2005 .

[34]  J. Zucman‐Rossi,et al.  Hepatocellular carcinoma , 1998, Nature Reviews Disease Primers.